Sino Biopharmaceutical Limited · HKEX:1177
Sino Biopharmaceutical — H1 2025 Earnings Presentation
27 slides from Sino Biopharmaceutical's earnings presentation, Aug 18, 2025
Slide 1: Sino Biopharmaceutical Limited 2025 Interim Results
Sh Bi AE See IRS) SINO BIOPHARMACEUTICAL LIMITED (BERS: 1177.HK) 2025.8.18 Bi
Slide 2: iP it
iP it
Slide 3: H1 2025 revenue and profit growth
WPAR SSR 202588 FMEA, Ue FITEHISCEM RT TAH A (AE&th 1270) PS A 140.2% 0 175.7 me A 101.1% 2024 H1 ea H1 2024 H1 ae H1 2024 H1 ae H1 HBBES FeaS HRBES BBS RBS RBS SE! 1) VRS VPA] AA): BOIQRNon-HKFRSAS SMA, AAPBAGALE—-H, AVUAGTHSEMAARMADSHKR, HIBNTHAMSOBNHRELUHBAASE 3
Slide 4: Profit attributable to shareholders
VASE (BAF) (AB&tB 1270) 2025H1 2024H1 a= RFF USREMT) 33.9 30.2 412.3% BAL4EVS ZRF SAAsASU SRA > 16.1 MARBADRABAR SIA FMR BUTR ARS HIRE) 0.0 0.9 ETAPRARZAERM SAR REZ UE (HBA BAL BIA) 3.3 0.5 RAVNBRAZA RNG SAAS), BRR GOMER GUTR IHS BIE) 0.1 0.1 AVR AD FIRB ABER AAA) 0.2 - FRMABASBIZ: ABRE 0.0 0.0 IC o
Slide 5: Innovative product revenue share rising to 27.2%
BUF ae WATE IK27.2%, HS ES RRS (ABBR 1270) Aine Poor Rw Q= SY zee SU al same HES BEe Rae ? 0 y) 3 TRE ASB Eat TE BAA OAT KA —e- Cla A SLE EAR ESR BERT Amana 44.4% 80% 27.2% Ose Kh G sue" Vz" @©™ Om 78.0 xeDe RAF? setae Ram faRIB® Sunt? 0 ? 4 DRAAS BREE BSR HMO «MER | AUTB AK ia B BEBE PAT ENR ENR Pu
Slide 6: R&D investment
RAR ARAMA, RRA MAS BoAer (ABT Zz) PURER IFA IL TARE (HE) SRR NWR 3K EA mm OR Sar (FRESE OBR ERR IAL 18.1% RADAR Dai we, 7 11.1% FEAT ARE fel RY g 7 ne Sno, _ PRAKZAUABRA =e, 2020 2021 2022 2023 2024 = -2024H1~—«2025H1 RE4E HS#E HSBE HEAR Hee SEL 1) 2025H1F RAR LEIA0S.7%, (HHT REDE. HSI HAR oe 6
Slide 7: Gross margin
SP ME. SA. TAI EIE, EARNS (A Bei 1270) i] (= Park M2614 10000L $mtes 4y Ei) (#) =F2cmPRt, BARR a SHI 82.8% 81.0% Ole 80.1% 78.1% 82.1% 82.5% — 2020 2021 2022 2023 2024 2024 H1 2025 H1 HE4S RBS HERE ARBRE HERE Gimmeanaey Tray nee, meme Tee Seo NRA
Slide 8: Expense ratios
EAS. ANKEREEH, AMMERDteA (ABBR 1270) KREARRE, AARAABS FE SAW SAGA, PRREAR BS CRMAKSALE, SHHERSAEA EREWERA THD A 21.8% 2020 2021 = 2022, 2028-2024 = 2024H1 © 2025H1 RAE HRS HREE HRB HAS SG&AR —e— SGC&ARME 49.2% 47.3% 4 45.0% 49 0% 42.1% | 43.1% 42.9% — 2020 ©2021 «2022 -2023«« 2024 | 2026H1 202511 WR
Slide 9: Cash flow and shareholder returns
RSS weNUSIN, KHRERKNRAGIR iE: (ABBR 1270) RRRSE REE PME 305 a8 2n1 an fe 30512 “= fhe 90 85 | | 2022 2023 2024 2025H1 PRES AS PA "20% W 1) ABMBAF22F6A AN RTE. MERRIBR LUSEK A; 126 120 a 2022 2023 2024 2025H1 TRS RHA EIS SRR See esses 20% +weomee as > beset 62% 12.5 11.6 14.2 2 ee a 5.0 | 54 38 27 2M
Slide 10: iP it
iP it
Slide 11: Innovative product launch plan 2025-2027
BU RTIR ED WAR SEERA, BRT Heat A ES RA Ora Orars D922 © ova @ wee OUR IRA AEE 50% QB3616 (CDK2/4/6#0#4%1)) BIG{F: Zongertinib (HERZM#IF) QP001 (RB SREB) STU ENREAARMAFVa Bi Aides Bait ASFARRUS 2025 55% M701 (CD3/EpCAMIRii) TQ05105 (JAK/ROCK HAF) PL-S (S7vigik) Naldemedine (u-Falh Ststai07) MLE (= tt
Slide 12: Oncology pipeline
DART ae S RUM eA iba ihe MASH | J | FLERE A y) is >? a copD Bl et rbd 29 7 Ph ea -.... abFt ee afl Seo NRA
Slide 13: Lung cancer pipeline
APF-FE) SRAM RS Sth SF) ae, BSH ORNS HORT A Fe) ORG (fr) SBD LM-2168 ReNTET TQB2101 LM-2168 (PD-1/CTLA-4™=) (ROR1 ADC) (PD-1/CTLA-4™«) TQB2101 LM-2199 js LM-2199 ee (Esa ee) nations (EGFR/VEGF) L317 Rp (NaPi2b ADC) BALE (55%) LM-2168 RIM ' rN LM.2199 LM-2168 L317 SBE HET iy (PD-1/CTLA-4™e) : (EGFR/V
Slide 14: Breast cancer pipeline
APS-FLRE REARIRESALEY, ARBRE ATR & SHO SURES) (3) 3B 24) Oa HR+ ToB3616 * (60-70%) (cDK2/4/ PEREPAME SS HER2 low (65% HR+, 35% TNBC) ARE 2HeE TNBC 798312; ~2308 (10-15%) (PARPLi) MABE 7982102 * HER2+ (HER23R#ADC) (15-20%) WERT T9B3616 * aoa PI3Ka. T9B2102 * (HER2S1RADC) ToB3616 ® TQB3915 sepnorne TQ
Slide 15: Gastrointestinal cancer pipeline
S-AiiGihe Ate, SEARE. BE BRE PRS 4 SHO SURES) Liz. She F~-s0HMeSS Be RE SRSF-100HHLES SRSS-SOHMLES SEBS 2HSH~-105MkSS RAS/BRAF WT MSI-H ITGB6 ADC LM-2168 R ER: (PD-1/CTLA-4™e) LM-350 m~ (CDH17 ADC) Gene LM-350 LM-2450 (COSFEP UTS) (41BB--4/cDH17) 4th TQB2930 LM-2199 (HER2I3A) (EGFR/VEGF) LM-2450 LM-
Slide 16: MASH pipeline
BR ia/ {tid OAR ES ITY, BES IR2(Z+MASH BS #2: MASHPRS BESTE eek > 1450) Om > 3AM IREW VAL, itwrcewznna «== DEARR © Madrigal ak=ro 89bIo : Dae La, : Laniitranor Resmetrom Etruxifermin Pegozatermin Semaglutide Survodutide 29 *hEIMASHD ARES MTF BIE : (pan PPAR) (THR) (ror2i) (eor2) (GLP-R) (eLP-1RiceR)
Slide 17: Respiratory and autoimmune pipeline
PIR / RMR RARER, Stt/Tin/RSSZALeoata 79c3302 (Ics/* T9c3721 ® C2731 T9C2938 T9¢3721 AMA/LABASK 2) (PDE3/4i0%4%H) (TSLP#4) (T2844) (PDE3/4i0%1%) SSUEPBSEtERDIA (COPD) Sht~5iZBS emg 237+ BS 79C2938 79C2731 (sT24i) (TSLP#i) TDIOL SS ATERBAT EL (IPF) BH~SOOR BE (ROCK2#0# 78) ene > pee ee] mez, rg, eer |
Slide 18: Innovative product launch timeline to 2030
SREY BAEC, IGEN IA LAR SH >. 2030 (A BeiB) Rah aL {20+} Revrl7= Bue Sw Ai ics FAO, Te onsen +I KABA Mice UT 0 ” TRD309, TRD310, ] : . > mit sas5IER (=H) DUH ADI EL/ SBS FEL wos Sean SRASRRRUES 2026 az? SSP BEM 7} BRAKE 2025 PAAR 2024 6 gare i HS-RERUS BE / ER? 2018 f t ALSS RRS i] = ° : = | | UZ =—
Slide 19: Key oncology assets
DART ae S RUM eA TQB2922 (EGFR/c-Met3Xiz) pag LM" 168 (CTLA-4™ER Iz) TQB6411 (EGFR/c-Met ADC) LM-2168 (PD-1/CTLA-4™E}Z #7) aeammanas LM-108 (CCR84#7) Ayay ~~ HARI TQB2868 (PD-1/TGF-BIIRERE EA) >. LM-350 (CDH17 ADC) TQB3616 (CDK2/4/6i) #1) TQB2102 (HER23Z#1ADC) 7 a Lanifibranor (32PPARM=H7) iFia EFI
Slide 20: TQB2922 and TQB6411 EGFR/c-Met
ibis: BRS Rant TQB2922 (EGFR/c-Met®2H#t), TQB6411 (EGFR/c-MetW4itADC) tak F—KtH1Z Ba ET) Ba Fiver 18 1196 8 ag bib TQB2922 EGFR/c-Met}tit BRA MS A UE RSF RINABIGER (JE) SRB RE) TQB6411 EGFR/c-Met}Q#1ADC. ARRAS ER WBE * 5SSPTSPMHRMat, RH EGER BAMA HI7 Hi BAUCHFRH, BTR. ROKK HHat, PSRs TQB2922 (EGFR/c
Slide 21: LM-168 and LM-2168 CTLA-4
fits: BSA ian LM-168 (CTLA-4™E2847), LM-2168 (PD-1/CTLA-4™ER $1) BHR GHIA IE FRE, aS ia Ra LM-168 CTLA-A™ER ET LM-2168 PD-1/CTLA-4™ERRGA, ia BE BAER BAA EAR Ra 18 18 | Is PR AT HPP GREP SE SPE TE — LE len - TR. REERB AS Cary ROT Ema Err (80 9/ER BER) R-factor 100 uM 10M >10000 Kynurenine — 169nM (CR
Slide 22: LM-108 CCR8
Gite: BRS sans LM-108 (CCR8i1) SERFICE A, ABRAAISH EUR “RP Bie” LM-108 CCRE#it PURE AT mA WCDEWARIRMEAT MEF + FARMS AMSAT eRe RAMSI-H /AMMRIREBS SS + AF —Atviar AICCREARM G/F ae Sea e REBTARWSEN BEATA + BPR TEST te TAMA (Ti-Tregs) SPD-1/PD- LIMZ4BX, CCREETi-Tregs LMBHHERIA + LM-108 ii 7APRTi-Tregs,
Slide 23: TQB2868 PD-1/TGF-β
Gia: BRS sans TQB2868 (PD-1/TGF-BUIAERAA SA) SERFICHH, “Se-BRA-tiir” =A el TQB2868 iE 18 185 18 Re PD-1/TGF-BXsEHS EA yet D> SRHRERBR 2025 ASCOBREBAR: FUSSOHM BSR ASAE Bal, SERMIPD-1/TGF-PMREMA SAR TOB2868RK SSeS BES thir AF — A ere PEAS AS AS AR) HLH, TORCH ARES Maximum Change in Tumor Size Percent
Slide 24: LM-350 CDH17 ADC
Ah: BES aantt LM-350 (CDH17 ADC) RB#S bite t-Sat ABH ERR CDH 1 7H ERAN Fae. LM-350 bated CDH17 ADC ARRAS UA COHI7F SiR hPa Shes, Same CDH177EL FARR Bik?): d, oa 42H CDXBD + ooveAAInAE + 86% AN BRE oo iene sags tat et oe i. vischas meen + To%by te MARI i é eo Venice WA aw + SOMERS Shae i 5 od i 500-
Slide 25: TQC3721 PDE3/4 inhibitor
FRR: BSE AM Mah TQC3721 (PDES/4i08l) FH. SALINE, BRAB, BESERBIC A. TQC3721 PDE3/4404 FI 3 Best-in-class HH + BRAS SABI 8K (PDES) MAX (PDEA) BIW WEE, SPDES, PODER RANG RS F ensifentrine AREER + BRISER—APDES4IMEI AL, PE MARL, TOCI721HREESRS we piven A 18 NbHAS#212+9 FI E2025 ERS#A TQC3721#84F COPD BS
Slide 26: Upcoming data readouts and milestones
BASE it kl Arh yer TQB3616 (CDK2/4/6i #477) + —#HR+/HER2-FL RAE MIRK [2025 ESMO] + CDKA4/6ifit25 7. ARE IMA [2026] TQB2102 (HER2IRIRADC) + HER2PRMESLARSE IDM [2025 ESMO] + HER2S¢8SRBi8 88 Ib/ IIMA [2025 ESMO Asia] + HERS: SS4E/| ARR RM IMA [2025 WCLC] M701 (CD3/EpCAM3R#) + BtEAa7k I/F [2025 ESMO] TQ
Slide 27: Slide 27
Sino Biopharmaceutical — H1 2025 Earnings Presentation on 6ix